Migraine Headache
Conditions
Keywords
Migraine, Headache
Brief summary
This is a Phase 2, multicenter, randomized, double-blind, placebo and active comparator-controlled study of LY2590443 in approximately 200 participants with migraines.
Interventions
DRUGLY2590443
200 milligrams (mg) as four 50-mg capsules, oral, once
DRUGPlacebo injection
saline solution, injection, once
DRUGSumatriptan
6 milligrams (mg) injection (0.5 milliliter \[mL\] of 12 mg/mL solution), once
DRUGPlacebo capsule
4 capsules, once
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Male and female participants between the ages of 18 and 65 years, inclusive. * Participants who have migraine headaches, with or without aura (diagnosis according the International Classification of Headache Disorders-II), for at least 1 year. * Participants who have had 2-8 migraine attacks on average per month for the last 3 months (but less than 15 headache days per month). * Participants who are willing and able to comply with the study schedule and requirements. * Participants who speak, read, and understand English sufficiently well and are willing to provide written informed consent. * Participants who in the opinion of the principal investigator are in good general health. * Venous access should be sufficient to allow blood sampling as per protocol.
Exclusion criteria
* Participants who do not or may not tolerate 5HT1 agonist treatments, with known hypersensitivity to sumatriptan (as discussed with the investigator). * Female participants who have a positive pregnancy test at screening or pre- dose evaluation, or are breastfeeding. * History or presence of significant medical illnesses as determined by the investigator. * Participants with a current clinical diagnosis of major psychiatric disease. * Regular use of known drugs of abuse; use of opiates for migraine rescue (no more than two times per month) is permissible. * Blood donation of 500 milliliter (mL) or greater of whole blood products within 4 weeks of study commencement, during the study, or 4 weeks following the study. * Investigator site personnel directly affiliated with this study and their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted. * Consumption of more than three units of alcohol per day where one unit is defined as a 12 ounces (oz) beer, 4 oz wine, or 2 oz of alcohol spirit liquor. * Are unwilling or unable to comply with the use of a diary to directly record data from the participant.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Headache Pain Free Response | 2 hours after study drug administration | Participants were required to assess the presence of a headache and grade the intensity of the headache as severe, moderate, mild, or none. Headache pain free response was defined as the number of participants with a migraine pain intensity score of none. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Pain Relief Response | 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, and 4 hours after study drug administration. | Participants were required to assess the presence of a headache and grade the intensity of the headache as severe, moderate, mild, or none. Pain relief response was defined as the number of participants with a migraine pain intensity score of none. |
| Number of Participants With Sustained Pain Relief Response | 24 and 48 hours after study drug administration | Participants were required to assess the presence of a headache and grade the intensity of the headache as severe, moderate, mild, or none. Sustained pain relief response was defined as the number of participants with no return of a moderate or severe headache after pain went down to mild or none at 2 hours. |
| Number of Participants With Recurrent Migraine Headache Within 24 or 48 Hours | Up to 24 and 48 hours after study drug administration | The time to headache recurrence is presented as the number of participants experiencing at least 1 recurring headache within 24 or 48 hours of receiving study drug. |
| Number of Participants With Nausea | Pre-dose, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, and 4 hours after study drug administration. | The number of participants reporting nausea as a migraine symptom |
| Number of Participants With Pain Free Response | 30 minutes, 1 hour, 1.5 hours, 3 hours, and 4 hours after study drug administration | Participants were required to assess the presence of a headache and grade the intensity of the headache as severe, moderate, mild, or none. Pain free response was defined as the number of participants with a migraine pain intensity score of none. |
| Number of Participants With Photophobia | Pre-dose, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, and 4 hours after study drug administration. | The number of participants reporting photophobia as a migraine symptom |
| Number of Participants With Vomiting | Pre-dose, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, and 4 hours after study drug administration. | The number of participants reporting vomiting as a migraine symptom |
| Number of Participants With Sustained Pain Free Response | 24 and 48 hours after study drug administration | Participants were required to assess the presence of a headache and grade the intensity of the headache as severe, moderate, mild, or none. Sustained pain free response was defined as the number of participants with no return of a mild, moderate or severe headache after pain intensity went down to none at 2 hours. |
| Number of Participants With Phonophobia | Pre-dose, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, and 4 hours after study drug administration. | The number of participants reporting phonophobia as a migraine symptom |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| LY2590443 200 milligrams (mg) administered once as four 50-mg capsules | 40 |
| Sumatriptan 6 milligrams (mg) administered once as an injection of 0.5 milliliter (mL) of 12 mg/mL solution | 40 |
| Placebo Administered once as 4 capsules or once as an injection of saline solution | 40 |
| Total | 120 |
Baseline characteristics
| Characteristic | LY2590443 | Total | Placebo | Sumatriptan |
|---|---|---|---|---|
| Age, Continuous | 40.30 years STANDARD_DEVIATION 12.4 | 39.10 years STANDARD_DEVIATION 11.98 | 37.48 years STANDARD_DEVIATION 10.58 | 39.53 years STANDARD_DEVIATION 12.94 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 4 Participants | 15 Participants | 7 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 36 Participants | 105 Participants | 33 Participants | 36 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 2 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 10 Participants | 27 Participants | 7 Participants | 10 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 3 Participants | 7 Participants | 1 Participants | 3 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 5 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) White | 25 Participants | 78 Participants | 29 Participants | 24 Participants |
| Region of Enrollment United States | 40 Participants | 120 Participants | 40 Participants | 40 Participants |
| Sex: Female, Male Female | 28 Participants | 83 Participants | 29 Participants | 26 Participants |
| Sex: Female, Male Male | 12 Participants | 37 Participants | 11 Participants | 14 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 13 / 40 | 16 / 40 | 3 / 40 |
| serious Total, serious adverse events | 0 / 40 | 0 / 40 | 0 / 40 |
Outcome results
Primary
Number of Participants With Headache Pain Free Response
Participants were required to assess the presence of a headache and grade the intensity of the headache as severe, moderate, mild, or none. Headache pain free response was defined as the number of participants with a migraine pain intensity score of none.
Time frame: 2 hours after study drug administration
Population: All participants who received at least 1 dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| LY2590443 | Number of Participants With Headache Pain Free Response | 6 Participants |
| Sumatriptan | Number of Participants With Headache Pain Free Response | 12 Participants |
| Placebo | Number of Participants With Headache Pain Free Response | 6 Participants |
Secondary
Number of Participants With Nausea
The number of participants reporting nausea as a migraine symptom
Time frame: Pre-dose, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, and 4 hours after study drug administration.
Population: All participants who received at least 1 dose of study drug.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| LY2590443 | Number of Participants With Nausea | 30 Minutes Post-dose | 13 Participants |
| LY2590443 | Number of Participants With Nausea | 2 Hours Post-dose | 8 Participants |
| LY2590443 | Number of Participants With Nausea | 1.5 Hours Post-dose | 8 Participants |
| LY2590443 | Number of Participants With Nausea | Pre-Dose | 18 Participants |
| LY2590443 | Number of Participants With Nausea | 4 Hours Post-dose | 4 Participants |
| LY2590443 | Number of Participants With Nausea | 3 Hours Post-dose | 6 Participants |
| LY2590443 | Number of Participants With Nausea | 1 Hour Post-dose | 13 Participants |
| Sumatriptan | Number of Participants With Nausea | 1.5 Hours Post-dose | 10 Participants |
| Sumatriptan | Number of Participants With Nausea | Pre-Dose | 16 Participants |
| Sumatriptan | Number of Participants With Nausea | 30 Minutes Post-dose | 19 Participants |
| Sumatriptan | Number of Participants With Nausea | 1 Hour Post-dose | 13 Participants |
| Sumatriptan | Number of Participants With Nausea | 2 Hours Post-dose | 8 Participants |
| Sumatriptan | Number of Participants With Nausea | 3 Hours Post-dose | 7 Participants |
| Sumatriptan | Number of Participants With Nausea | 4 Hours Post-dose | 4 Participants |
| Placebo | Number of Participants With Nausea | 2 Hours Post-dose | 6 Participants |
| Placebo | Number of Participants With Nausea | 30 Minutes Post-dose | 19 Participants |
| Placebo | Number of Participants With Nausea | 4 Hours Post-dose | 2 Participants |
| Placebo | Number of Participants With Nausea | 3 Hours Post-dose | 3 Participants |
| Placebo | Number of Participants With Nausea | 1.5 Hours Post-dose | 8 Participants |
| Placebo | Number of Participants With Nausea | 1 Hour Post-dose | 12 Participants |
| Placebo | Number of Participants With Nausea | Pre-Dose | 25 Participants |
Secondary
Number of Participants With Pain Free Response
Participants were required to assess the presence of a headache and grade the intensity of the headache as severe, moderate, mild, or none. Pain free response was defined as the number of participants with a migraine pain intensity score of none.
Time frame: 30 minutes, 1 hour, 1.5 hours, 3 hours, and 4 hours after study drug administration
Population: All participants who received at least 1 dose of study drug.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| LY2590443 | Number of Participants With Pain Free Response | 3 Hours Post-dose | 14 Participants |
| LY2590443 | Number of Participants With Pain Free Response | 1.5 Hours Post-dose | 3 Participants |
| LY2590443 | Number of Participants With Pain Free Response | 30 Minutes Post-dose | 7 Participants |
| LY2590443 | Number of Participants With Pain Free Response | 1 Hour Post-dose | 1 Participants |
| LY2590443 | Number of Participants With Pain Free Response | 4 Hours Post-dose | 25 Participants |
| Sumatriptan | Number of Participants With Pain Free Response | 1.5 Hours Post-dose | 10 Participants |
| Sumatriptan | Number of Participants With Pain Free Response | 30 Minutes Post-dose | 8 Participants |
| Sumatriptan | Number of Participants With Pain Free Response | 1 Hour Post-dose | 5 Participants |
| Sumatriptan | Number of Participants With Pain Free Response | 3 Hours Post-dose | 19 Participants |
| Sumatriptan | Number of Participants With Pain Free Response | 4 Hours Post-dose | 30 Participants |
| Placebo | Number of Participants With Pain Free Response | 4 Hours Post-dose | 24 Participants |
| Placebo | Number of Participants With Pain Free Response | 3 Hours Post-dose | 13 Participants |
| Placebo | Number of Participants With Pain Free Response | 30 Minutes Post-dose | 4 Participants |
| Placebo | Number of Participants With Pain Free Response | 1.5 Hours Post-dose | 5 Participants |
| Placebo | Number of Participants With Pain Free Response | 1 Hour Post-dose | 2 Participants |
Secondary
Number of Participants With Pain Relief Response
Participants were required to assess the presence of a headache and grade the intensity of the headache as severe, moderate, mild, or none. Pain relief response was defined as the number of participants with a migraine pain intensity score of none.
Time frame: 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, and 4 hours after study drug administration.
Population: All participants who received at least 1 dose of study drug.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| LY2590443 | Number of Participants With Pain Relief Response | 30 Minutes Post-dose | 7 Participants |
| LY2590443 | Number of Participants With Pain Relief Response | 1 Hour Post-dose | 11 Participants |
| LY2590443 | Number of Participants With Pain Relief Response | 1.5 Hours Post-dose | 17 Participants |
| LY2590443 | Number of Participants With Pain Relief Response | 2 Hours Post-dose | 22 Participants |
| LY2590443 | Number of Participants With Pain Relief Response | 3 Hours Post-dose | 34 Participants |
| LY2590443 | Number of Participants With Pain Relief Response | 4 Hours Post-dose | 38 Participants |
| Sumatriptan | Number of Participants With Pain Relief Response | 4 Hours Post-dose | 39 Participants |
| Sumatriptan | Number of Participants With Pain Relief Response | 30 Minutes Post-dose | 8 Participants |
| Sumatriptan | Number of Participants With Pain Relief Response | 2 Hours Post-dose | 31 Participants |
| Sumatriptan | Number of Participants With Pain Relief Response | 3 Hours Post-dose | 35 Participants |
| Sumatriptan | Number of Participants With Pain Relief Response | 1 Hour Post-dose | 14 Participants |
| Sumatriptan | Number of Participants With Pain Relief Response | 1.5 Hours Post-dose | 25 Participants |
| Placebo | Number of Participants With Pain Relief Response | 1 Hour Post-dose | 12 Participants |
| Placebo | Number of Participants With Pain Relief Response | 1.5 Hours Post-dose | 18 Participants |
| Placebo | Number of Participants With Pain Relief Response | 4 Hours Post-dose | 34 Participants |
| Placebo | Number of Participants With Pain Relief Response | 2 Hours Post-dose | 24 Participants |
| Placebo | Number of Participants With Pain Relief Response | 30 Minutes Post-dose | 4 Participants |
| Placebo | Number of Participants With Pain Relief Response | 3 Hours Post-dose | 35 Participants |
Secondary
Number of Participants With Phonophobia
The number of participants reporting phonophobia as a migraine symptom
Time frame: Pre-dose, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, and 4 hours after study drug administration.
Population: All participants who received at least 1 dose of study drug.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| LY2590443 | Number of Participants With Phonophobia | 30 Minutes Post-dose | 24 Participants |
| LY2590443 | Number of Participants With Phonophobia | 2 Hours Post-dose | 11 Participants |
| LY2590443 | Number of Participants With Phonophobia | 1.5 Hours Post-dose | 15 Participants |
| LY2590443 | Number of Participants With Phonophobia | Pre-Dose | 28 Participants |
| LY2590443 | Number of Participants With Phonophobia | 4 Hours Post-dose | 4 Participants |
| LY2590443 | Number of Participants With Phonophobia | 3 Hours Post-dose | 6 Participants |
| LY2590443 | Number of Participants With Phonophobia | 1 Hour Post-dose | 19 Participants |
| Sumatriptan | Number of Participants With Phonophobia | 1.5 Hours Post-dose | 18 Participants |
| Sumatriptan | Number of Participants With Phonophobia | Pre-Dose | 33 Participants |
| Sumatriptan | Number of Participants With Phonophobia | 30 Minutes Post-dose | 25 Participants |
| Sumatriptan | Number of Participants With Phonophobia | 1 Hour Post-dose | 20 Participants |
| Sumatriptan | Number of Participants With Phonophobia | 2 Hours Post-dose | 13 Participants |
| Sumatriptan | Number of Participants With Phonophobia | 3 Hours Post-dose | 3 Participants |
| Sumatriptan | Number of Participants With Phonophobia | 4 Hours Post-dose | 1 Participants |
| Placebo | Number of Participants With Phonophobia | 2 Hours Post-dose | 12 Participants |
| Placebo | Number of Participants With Phonophobia | 30 Minutes Post-dose | 26 Participants |
| Placebo | Number of Participants With Phonophobia | 4 Hours Post-dose | 3 Participants |
| Placebo | Number of Participants With Phonophobia | 3 Hours Post-dose | 5 Participants |
| Placebo | Number of Participants With Phonophobia | 1.5 Hours Post-dose | 16 Participants |
| Placebo | Number of Participants With Phonophobia | 1 Hour Post-dose | 22 Participants |
| Placebo | Number of Participants With Phonophobia | Pre-Dose | 31 Participants |
Secondary
Number of Participants With Photophobia
The number of participants reporting photophobia as a migraine symptom
Time frame: Pre-dose, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, and 4 hours after study drug administration.
Population: All participants who received at least 1 dose of study drug.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| LY2590443 | Number of Participants With Photophobia | 30 Minutes Post-dose | 33 Participants |
| LY2590443 | Number of Participants With Photophobia | 2 Hours Post-dose | 22 Participants |
| LY2590443 | Number of Participants With Photophobia | 1.5 Hours Post-dose | 25 Participants |
| LY2590443 | Number of Participants With Photophobia | Pre-Dose | 38 Participants |
| LY2590443 | Number of Participants With Photophobia | 4 Hours Post-dose | 6 Participants |
| LY2590443 | Number of Participants With Photophobia | 3 Hours Post-dose | 12 Participants |
| LY2590443 | Number of Participants With Photophobia | 1 Hour Post-dose | 31 Participants |
| Sumatriptan | Number of Participants With Photophobia | 1.5 Hours Post-dose | 23 Participants |
| Sumatriptan | Number of Participants With Photophobia | Pre-Dose | 37 Participants |
| Sumatriptan | Number of Participants With Photophobia | 30 Minutes Post-dose | 31 Participants |
| Sumatriptan | Number of Participants With Photophobia | 1 Hour Post-dose | 28 Participants |
| Sumatriptan | Number of Participants With Photophobia | 2 Hours Post-dose | 19 Participants |
| Sumatriptan | Number of Participants With Photophobia | 3 Hours Post-dose | 9 Participants |
| Sumatriptan | Number of Participants With Photophobia | 4 Hours Post-dose | 4 Participants |
| Placebo | Number of Participants With Photophobia | 2 Hours Post-dose | 24 Participants |
| Placebo | Number of Participants With Photophobia | 30 Minutes Post-dose | 36 Participants |
| Placebo | Number of Participants With Photophobia | 4 Hours Post-dose | 6 Participants |
| Placebo | Number of Participants With Photophobia | 3 Hours Post-dose | 10 Participants |
| Placebo | Number of Participants With Photophobia | 1.5 Hours Post-dose | 27 Participants |
| Placebo | Number of Participants With Photophobia | 1 Hour Post-dose | 31 Participants |
| Placebo | Number of Participants With Photophobia | Pre-Dose | 38 Participants |
Secondary
Number of Participants With Recurrent Migraine Headache Within 24 or 48 Hours
The time to headache recurrence is presented as the number of participants experiencing at least 1 recurring headache within 24 or 48 hours of receiving study drug.
Time frame: Up to 24 and 48 hours after study drug administration
Population: All participants who received at least 1 dose of study drug with evaluable migraine recurrence data.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| LY2590443 | Number of Participants With Recurrent Migraine Headache Within 24 or 48 Hours | 24 Hours Post-dose | 2 Participants |
| LY2590443 | Number of Participants With Recurrent Migraine Headache Within 24 or 48 Hours | 48 Hours Post-dose | 6 Participants |
| Sumatriptan | Number of Participants With Recurrent Migraine Headache Within 24 or 48 Hours | 24 Hours Post-dose | 2 Participants |
| Sumatriptan | Number of Participants With Recurrent Migraine Headache Within 24 or 48 Hours | 48 Hours Post-dose | 4 Participants |
| Placebo | Number of Participants With Recurrent Migraine Headache Within 24 or 48 Hours | 24 Hours Post-dose | 4 Participants |
| Placebo | Number of Participants With Recurrent Migraine Headache Within 24 or 48 Hours | 48 Hours Post-dose | 6 Participants |
Secondary
Number of Participants With Sustained Pain Free Response
Participants were required to assess the presence of a headache and grade the intensity of the headache as severe, moderate, mild, or none. Sustained pain free response was defined as the number of participants with no return of a mild, moderate or severe headache after pain intensity went down to none at 2 hours.
Time frame: 24 and 48 hours after study drug administration
Population: All participants who received at least 1 dose of study drug and had Sustained Pain Free Response data.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| LY2590443 | Number of Participants With Sustained Pain Free Response | Pain Free at 24 Hours Post-dose | 5 Participants |
| LY2590443 | Number of Participants With Sustained Pain Free Response | Pain Free at 48 Hours Post-dose | 5 Participants |
| Sumatriptan | Number of Participants With Sustained Pain Free Response | Pain Free at 24 Hours Post-dose | 11 Participants |
| Sumatriptan | Number of Participants With Sustained Pain Free Response | Pain Free at 48 Hours Post-dose | 9 Participants |
| Placebo | Number of Participants With Sustained Pain Free Response | Pain Free at 24 Hours Post-dose | 6 Participants |
| Placebo | Number of Participants With Sustained Pain Free Response | Pain Free at 48 Hours Post-dose | 6 Participants |
Secondary
Number of Participants With Sustained Pain Relief Response
Participants were required to assess the presence of a headache and grade the intensity of the headache as severe, moderate, mild, or none. Sustained pain relief response was defined as the number of participants with no return of a moderate or severe headache after pain went down to mild or none at 2 hours.
Time frame: 24 and 48 hours after study drug administration
Population: All participants who received at least 1 dose of study drug and had Sustained Pain Relief Response data.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| LY2590443 | Number of Participants With Sustained Pain Relief Response | Pain Relief at 24 Hrs Post-dose | 19 Participants |
| LY2590443 | Number of Participants With Sustained Pain Relief Response | Pain Relief at 48 Hrs Post-dose | 19 Participants |
| Sumatriptan | Number of Participants With Sustained Pain Relief Response | Pain Relief at 24 Hrs Post-dose | 28 Participants |
| Sumatriptan | Number of Participants With Sustained Pain Relief Response | Pain Relief at 48 Hrs Post-dose | 27 Participants |
| Placebo | Number of Participants With Sustained Pain Relief Response | Pain Relief at 24 Hrs Post-dose | 24 Participants |
| Placebo | Number of Participants With Sustained Pain Relief Response | Pain Relief at 48 Hrs Post-dose | 23 Participants |
Secondary
Number of Participants With Vomiting
The number of participants reporting vomiting as a migraine symptom
Time frame: Pre-dose, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, and 4 hours after study drug administration.
Population: All participants who received at least 1 dose of study drug.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| LY2590443 | Number of Participants With Vomiting | 30 Minutes Post-dose | 0 Participants |
| LY2590443 | Number of Participants With Vomiting | 2 Hours Post-dose | 1 Participants |
| LY2590443 | Number of Participants With Vomiting | 1.5 Hours Post-dose | 1 Participants |
| LY2590443 | Number of Participants With Vomiting | Pre-Dose | 1 Participants |
| LY2590443 | Number of Participants With Vomiting | 4 Hours Post-dose | 0 Participants |
| LY2590443 | Number of Participants With Vomiting | 3 Hours Post-dose | 0 Participants |
| LY2590443 | Number of Participants With Vomiting | 1 Hour Post-dose | 1 Participants |
| Sumatriptan | Number of Participants With Vomiting | 1.5 Hours Post-dose | 1 Participants |
| Sumatriptan | Number of Participants With Vomiting | Pre-Dose | 1 Participants |
| Sumatriptan | Number of Participants With Vomiting | 30 Minutes Post-dose | 2 Participants |
| Sumatriptan | Number of Participants With Vomiting | 1 Hour Post-dose | 1 Participants |
| Sumatriptan | Number of Participants With Vomiting | 2 Hours Post-dose | 0 Participants |
| Sumatriptan | Number of Participants With Vomiting | 3 Hours Post-dose | 0 Participants |
| Sumatriptan | Number of Participants With Vomiting | 4 Hours Post-dose | 0 Participants |
| Placebo | Number of Participants With Vomiting | 2 Hours Post-dose | 0 Participants |
| Placebo | Number of Participants With Vomiting | 30 Minutes Post-dose | 1 Participants |
| Placebo | Number of Participants With Vomiting | 4 Hours Post-dose | 0 Participants |
| Placebo | Number of Participants With Vomiting | 3 Hours Post-dose | 0 Participants |
| Placebo | Number of Participants With Vomiting | 1.5 Hours Post-dose | 0 Participants |
| Placebo | Number of Participants With Vomiting | 1 Hour Post-dose | 0 Participants |
| Placebo | Number of Participants With Vomiting | Pre-Dose | 2 Participants |